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Cancer is second leading cause of death in the United States. Improving
cancer care through patient care, research, education and prevention not only
saves lives, but reduces health care cost as well. Breast cancer is the most
leading cause of cancer incidence and cancer related death in women of the
United States. 14-3-3s are a family of conserved proteins ubiquitously expressed
in all eukaryotic organisms. They form complexes with hundreds of proteins by
binding to specific phospho-serine/threonine containing motifs. In this way they
regulate a variety of cellular processes and are involved in many human
diseases especially cancer to our interest. Our lab and others recently reported
that the 14-3-3ζ (zeta) isoform is overexpressed in ~45% breast cancers, which
predicted poor patient outcome. 14-3-3ζ overexpression confers chemotherapy
resistance. Additionally, 14-3-3ζ prevents anoikis by suppressing p53 and
promotes epithelial mesenchymal transition by activating the TGB-β signaling
pathway, which plays important roles during tumor formation and progression.
Based on these l hypothesized that 14-3-3ζ plays an important role in breast
cancer.
vi

To systematically study the role of 14-3-3ζ in breast cancer in vivo, I
generated a strong 14-3-3ζ hypomorphic mutant mouse model by Gene Trap.
We found that the homozygous mutant mice are lethal neonatally due to
respiratory failure. This lethality could be rescued when outbred to CD-1 or
backcrossed to FVB/N mouse strain.

Early mammary gland development was not significantly affected in 14-33ζ homozygous mutant mice. When crossed with MMTV driven Polyoma MiddleT or Neu oncogene transgenic tumor prone mouse, the 14-3-3ζ mutant mice had
longer tumor latency and reduced lung metastasis compared to their wild type
counterpart. The tumor samples from the 14-3-3ζ mutant mice displayed
reduced proliferation, increased apoptosis and reduced angiogenesis. Multiple
genes were differentially expressed in the 14-3-3ζ knockout tumors. MiR-126
was an important microRNA mediating both the lethality and tumorigenesis
inhibition phenotype.

In addition, 14-3-3ζ knockout mice are smaller than their litter mates. This
growth retardation was accompanied with reduced growth hormone but
increased IGF-1 level in the circulation. The knockout mice had a defect in
glucose homeostasis. They have lower blood glucose and tolerate glucose
better than their wild type counterparts due to reduced glucose uptake. The
aberrant glucose homeostasis was accompanied by reduced Hif1-α and Igf1r
expression.
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The 14-3-3ζ knockout mice had other phenotypes that need to be further
characterized. This mouse strain provided new resource to study 14-3-3ζ
function in vivo and potentially could benefit patients that have aberrant
expression of 14-3-3ζ.
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Chapter 1

Introduction
1.1 Cancer

1.1a Definition

Cancer, also termed as malignant neoplasm, is defined as a group of
more than 100 diseases in which cells in a part of the body display uncontrolled
growth, invade and destroy adjacent tissues, and very often spread to other
locations of the body through lymphatic system or blood stream known as
metastasis. It is different from benign tumor in which the cells do not proliferate
without control, invade locally or metastasize to distant organs. Cancer, if left
untreated, can cause serious illness and even death.

1.1b Cause

Cancer can be an inheritable genetic disease, like BRCA1/2 gene
mutation in breast cancer, APC gene deletion in colon cancer and PTEN loss in
many types of cancers. However, the majority of cancers are caused by
environmental factors like exposure to alcohol, smoking, radiation, infection, diet
and exercise etc. The most significant risk factor is aging.
1.1c Statistics

1

Cancer is the second leading cause of death in the states. More than 11
million people are suffering from cancer nowadays according to National Cancer
Institute's Surveillance Epidemiology and End Results (SEER) database. It is
estimated that about 40% people will develop cancer in their lifetime and more
than 20% will die from it. The cost of cancer is more than 228 billion dollars
annually. Improving cancer care through patient care, research, prevention and
education is critical not only for eliminating cancer mediated suffering and death,
but also for helping to keep the nation in good financial figure.
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1.2 Breast cancer

1.2a Definition
According to the definition of National Cancer Institute, breast cancer is
the type of neoplasm that forms in tissues of the breast, usually the ducts (tubes
that carry milk to the nipple) and lobules (glands that make milk). It occurs in
both men and women, although male breast cancer is rare. Like most cancers,
breast cancer is influenced by many risk factors, like heritable genetic mutations,
exposure to toxic chemicals, diet and living styles etc.

1.2b Statistics
Breast cancer is the most leading cause of cancer incidence and cancer
related death in women of the United States. It is estimated that 230,480 women
will develop breast cancer this year, and 39,520 will die from it. About one out of
eight women will develop breast cancer in their life time. Thanks to the recent
breast cancer care improvement, breast cancer is highly treatable if detected
early with combination of surgery, chemotherapy, radiation therapy and hormone
therapy. The five-year survival rate of breast cancer, when diagnosed at
localized primary site, is over 98%. However, this rate drops to 23.4% if
diagnosed as metastatic disease (data obtained from American Society of
Cancer online).

1.2c Research models

3

Breast cancer development has been modeled as a multi-step process starting
from normal mammary epithelium to ductal hyperplasia, atypical ductal
hyperplasia (ADH), ductal carcinoma in situ (DCIS), invasive carcinoma, ending
with tumors capable of metastasizing to distant organs. These steps are defined
by a series of morphological changes based on epidemiological and histological
observations (Figure 1) (1, 2). This model has been wildly used to understand
how breast cancer initiate and progress into killing disease.

However, breast cancer is not a single disease but a collection of
heterogeneous diseases that have distinct histopathological features, genetic
variability and diverse prognostic outcomes. It is realized that no individual
model can completely recapitulate this complex disease (3).

Currently breast cancer cell lines, xenografts and genetically engineered
mouse models are widely used in the field of breast cancer research to
understand breast cancer from different angles (3).

4

Figure. 1 Schematic of breast cancer tumorigenesis and
progression
Polyak K. et. al. 2001
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1.3 14-3-3 family proteins

1.3a General property
14-3-3s are a 28-33kd conserved family proteins ubiquitously expressed
in all eukaryotic organisms (4). They were first found in 1967 as abundant
proteins in bovine brain. The name of 14-3-3 was determined by their fraction
number on a 2D DEAE-cellulose chromatography and the migration position in
subsequent starch gel electrophoresis (5). They comprise about 1% soluble
protein in the brain (6).

There are 7 highly homologous isoforms in mammals, namely β, γ, ε, σ, ζ,
τ and η (7). 14-3-3s are highly conserved proteins. There are 2 isoforms in yeast
and drosophila, and there are 15 isoforms in plants. The Saccharomyces
cerevisiae isoform BMH1 share ~70% amino acid sequence homology with
mammalian 14-3-3ε isoform. This similarity strongly suggest high degree of
functional conservation (8).

1.3b Function discovery
It was not until 20 years after the initial discovery, was the first function of
14-3-3 discovered as an activator of tryptophan and tyrosine hydroxylases which
is necessary for dopamine synthesis and other neurotransmitters (9).

14-3-3 binds to a variety of target proteins many of which are involved in
cancer including receptors like IGF1R(10, 11), kinases like Raf-1 (12-17) and
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Bcr (18), docking molecules like insulin receptor substrate I (IRS-1) (19) and
p130Cas (20), phosphotase like Cdc25 (21), death regulator like Bad (22), and
oncogene products like Polyoma-virus middle tumor antigen (PyMT) (23) and
Bcr-Abl (18), which indicated that 14-3-3 could be potential oncogene (24).
These findings of 14-3-3s interaction with different targets in biochemical and
genetic screenings reflected the physiological importance of 14-3-3s in diverse
cellular pathways (8).

As 14-3-3 lack endogenous enzymatic activity, it was thought to be
allosteric cofactor or molecular chaperone to affect the target proteins enzymatic
activity, subcellular localization, protein stability, interaction with other molecules
and post-translational modification (4).

1.3c Target interaction

Although 14-3-3 can bind to the target proteins independent of
phosphorylation, 14-3-3 binds to their ligands mainly in a phosphorylation
depedent manner. 14-3-3 is the first protein family that binds to specific
phospho-serine/threonine containing motif (25, 26). By screening oriented
peptide library, two consensus motifs were found to interact with 14-3-3,
RSXpSXP (mode 1) and RXXXpSXP (mode 2), where pS represents
phosphoserine (27, 28).
1.3d Structure basis

7

14-3-3s are highly homologous in their amino acid sequence (8). It is
predicted that the each isoform may have specific functions. However, the
structure studies did not support this hypothesis. 14-3-3 isoforms are highly
similar in their dimeric structure (27-30). Crystal structure indicated that 14-3-3
forms heterodimer or homodimer in cells. The 14-3-3ζ dimer is in a flattened
horseshoe shape. Each monomer contains 9 α-helices that are organized in an
anti-parallel manner. The first 4 helices are necessary to form the dimer. The
helices-3, 5, 7, 9 composed a conserved amphipathic binding groove(29) . This
structure is conserved in all 14-3-3 isoforms (28). (Figure 2, 3)

8

Figure 2. Crystal structure of 14-3-3ζ dimer. The red part indicates 14-3-3ζ
structure. The blue part indicates the 14-3-3 binding motif in integrin beta2
variant chain. The yellow part indicates the phosphorylated threonine site.
Diagram generated by PyMOL software using PDB ID# 2V7D
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Figure 3. 14-3-3s share high similarity in their amino acid sequence and crystal
structure. Ten 14-3-3 proteins from different species were aligned with
CLUSTAL algorithm. α-helices are indicated above the sequence using black
rectangles. Nucleus exportation signal sequence was colored in yellow below
the sequence. 5 blocks with highest sequence homology are shaded in purple
and the residues responsible for direct target binding are shaded in red.
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1.3e Regulation of 14-3-3

The isoform specific functions of 14-3-3s could be achieved by at least 3 ways,
strict regulation of cell type specific isoform expression, post-translational
modification and regulation of the availability (8, 24). The brain constitutively
expresses most 14-3-3 isoforms, whereas the other tissues express mainly one
or another isoform (31-33). 14-3-3 can be phosphorylated at S58 (34), S184 (35)
and T232 (36). These phosphorylatioin either inhibited the dimerization of 14-3-3
monomers or inhibited 14-3-3 binding to the target proteins, which inhibited 143-3 function. The cell can also express fluctuated level of 14-3-3 ligands, thus
competitively regulating the availability of 14-3-3 to other target proteins.(37-39)

1.3f Specificity function of 14-3-3 isoforms

Recent studies have revealed that each 14-3-3 isoform preferentially
binds to their target proteins and is involved in different biological processes and
human diseases. 14-3-3σ has been known to stabilize p53 and hence
suppresses tumor growth (40-42) and is frequently lost in cancer (43-46). 14-33σ also binds to Par3 and regulate cell polarity (47). 14-3-3ε binds to TGFβRI
thereby enhancing TGF-β signaling (48). 14-3-3ε can also bind to PolyA
polymerase and regulates its cellular localization (49). Loss of 14-3-3ε in mouse
models results in embryonic lethality and haplo-insufficiency leading to neuronal
development defects which mimics the human Miller-Dieker Syndrome (MDS)
(50). 14-3-3γ binds to PKC and regulates PDGF signaling in vascular smooth
muscle cells (51). Mice with targeted deletion of 14-3-3γ did not show any
11

obvious phenotype (52). 14-3-3τ regulates E2F stability and is required for
autophagy (53). 14-3-3τ knockout mice were embryonic lethal. 14-3-3τ
heterozygous mice were haploinsufficient and were sensitive to myocardial
infarction (54).

So although 14-3-3 isoforms are highly homologous and structurally
similar to each other, they have different function both in vitro and in vivo.
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1.4 14-3-3ζ
ζ

1.4a 14-3-3ζ
ζ in human diseases

Among all the 14-3-3 isoforms, the 14-3-3ζ (zeta) has been demonstrated to be
involved in several human diseases, like Creulzfeldt-Jakob Disease (CJD) (55),
Alzheimer Disease (33, 56), progressive multifocal leukoencephalopathy (PML)
(57), atherosclerosis (58), Huntington disease (59) and especially multiple
cancer types including lung (60, 61), breast (62, 63), ovarian (64), head and
neck (65), oral cancers (66) and lymphomas (67). These data support the idea
that 14-3-3ζ is critical in human diseases. However, how exactly 14-3-3ζ
functions in these diseases remain to be explored. Studying the role of 14-3-3ζ
could provide new opportunities to develop better therapy and potentially benefit
the patients. It is urgent to develop animal model in which 14-3-3ζ expression
could be manipulated to study the role of 14-3-3ζ in vivo. Unfortunately no such
animal models have been reported and available to the field so far.

1.4b 14-3-3ζ
ζ in breast cancer

14-3-3ζ isoform is. It is located on chromosome 8q22 which is frequently
amplified in breast cancer (68). We and others have shown that 14-3-3ζ is
overexpressed in ~45% breast cancer patients mainly due to amplification which
predicts poor clinic outcome (62). Overexpression of 14-3-3ζ resulted in
chemotherapy resistance in breast cancers (68). 14-3-3ζ activates Akt,
suppresses p53 and hence rendering the cells resistant to apoptosis (69). 14-313

3ζ can bind to TGFβRI, stabilize it and promotes epithelial-to-mesenchymal
transition (EMT). It also cooperates with ErbB2 to promote early stage breast
lesion to invasive breast cancer (63). All these data suggest that 14-3-3ζ plays
important role in breast cancer. 14-3-3ζ can be a potential therapeutic target in
breast cancer and other cancer types (70)

14

1.5 MicroRNA-126

MicroRNAs are a class of ~22 nucleotide noncoding RNAs that regulate gene
expression by either promoting mRNA degradation or repressing protein
translation (71). Hundreds of microRNAs have been identified in human and
other eukaryotes. Many of them are transcribed from introns of protein coding
genes or intergenic sequences. MicroRNAs are initially transcribed as large primicroRNAs in the nuclear. After cleavage by Drosha complex, pre-microRNAs
will be generated and translocated into the cytoplasm. Then the ribonuclease
Dicer and its cofactors will process the precursors into 19-25nt microRNA
duplexes. The microRNA heteroduplex will incorporate into RNA-induced
silencing complex (RISC) where the microRNAs could target specific mRNA
through complementary binding to the 3’-UTR region. In animals the 5’ proximal
“seeding” sequences (nucleotide 2 to 8) appear to be the major determinant of
paring specificity (72, 73). More than one-third human genes could be regulated
by microRNAs (74). The opposite strand known as star (*) strand is generally
degraded. In this way MicroRNAs regulate a wide variety of biological processes
(75).

MicroRNA-126is located in the intron 7 of EGFL7 gene (76). It will transcribe into
2 mature miRNAs, miR-126 and miR126*. MiR-126 expression was detected in
all tissues with the highest in heart and lung. MiR-126 is an endothelial specific
microRNA that regulates vascular integrity and angiogenesis (76-78).Targeted
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deletion of miR-126 resulted in lethality and lung deflation along with vascular
leakage, edema and hemorrhaging (76).

MiR-126 has been reported to involve in several human diseases such as type II
diabetes (79), malaria (80), coronary artery disease (81) cystic fibrosis (82) and
cancer (83-86). Its role in cancer has remained controversial and need to be
elucidated in the future (87).

16

Rationale, Purpose and Significance

According to the previous introduction, I hypothesized that 14-3-3ζ plays
important role in breast cancer formation and progression. Better understanding
the role of 14-3-3ζ in breast cancer could help us understand this disease better.
I would like to test this hypothesis in a genetically engineered mouse (GEM)
model which could collectively demonstrate breast cancer biology in vivo.

Our lab previously found that knocking down 14-3-3ζ using siRNAs sensitized
breast cancer cells to stress induced apoptosis without affecting its most
homologous isoform, 14-3-3β (62), which suggested that 14-3-3ζ had specific
important functions that could not be compensated by other 14-3-3 isoforms.

14-3-3ζ gene is located on mouse genome chromosome 15 without any other
known genes or non-coding RNAs located inside or close to that region, which
made the knockout of 14-3-3ζ feasible. Any phenotype observed in the 14-3-3ζ
gene knockout mouse is likely to be specific to loss of 14-3-3ζ alone.

So I decided to generate a 14-3-3ζ knockout mouse strain, in which I could
study the function of 14-3-3ζ in vivo. Meanwhile I could initiate to test whether
14-3-3ζ could be a cancer therapeutic target. This study could potentially benefit
a big proportion of patients who had aberrant regulation of 14-3-3ζ.

17

Chapter 2 Material and Methods

2.1 14-3-3ζ
ζ knockout Mice Generation and Maintenance

ES cell line RRR334 was obtained from Mutant Mouse Regional
Resource Center (MMRRC). RT-PCR was performed to confirm that the cell line
inactivates 14-3-3ζ. The primer sequence for the exogenous was forward: 5’TGCTGAGAAAAAGCAGCAGA and reverse: 5’GACAGTATCGGCCTCAGGAAGATCG. The primer sequence for endogenous
14-3-3ζ ctrl PCR was forward: 5’- TGCTGAGAAAAAGCAGCAGA and reverse:
5’- TTGTCATCACCAGCAGCAAC. Genetic Engineered Mouse Facility at MD
Anderson Cancer Center injected the cells into C57Bl/6 albino blastocysts. The
chimera mice were mated with C57Bl/6 albino mice to test germline transmission
and get 14-3-3ζ knockout founder mice. The primer sequences for PCR
genotyping were forward: 5’- CAACCATGTTGGGATAGAGG homologous to 143-3ζ intron 3, reverse: 5’- CCAAATAAGCCTTCCCTTCC homologous to intron 3
and 5’- AAGGGTCTTTGAGCACCAGA homologous to the gene trap vector. The
PCR will generate a 954bp fragment from the wild type allele and a 544bp
fragment from the mutant allele. Mice were backcrossed into C57Bl/6, FVB/N
congenic background or outbred to CD-1 genetic background respectively and
maintained since then. The C57Bl/6J and FVB/NJ mouse breeders were
purchased from the Jackson Laboratory, Bar Harbor, Maine. The CD-1 breeders
were purchased from Charles Rivers, Wilmington, MA.
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2.2 Mammary Gland Whole Mounts

The number 4 mammary glands on the left side of the mice were spread onto
microscopic slides, fixed in Carnoy's fixative overnight, hydrated and stained
with carmine alum stain (Sigma, St. Louis, Mo) overnight, and were then
dehydrated through sequential ethanol, treated with xylene to remove fat, and
mounted with Secure Mount (Fisher Scientific, Pittsburgh, PA) and cover slips.
Mammary gland tissue samples were collected during all phases of the estrous
cycle. The samples were imaged using Zeiss Discovery V20 dissection
microscope and axiom imaging software that came with the microscope.
2.3 Tissue Collection and Histological Analysis

The mouse embryos were collected by C-section at 18.5dpc. The lung tissues
were collected after euthanasia following IACUC.
Mammary tumor formation was monitored by palpation twice a week. Upon
formation of a palpable tumor, the mice were observed for 3-4 weeks for tumor
progression. When the tumor diameter reached 15mm, the mammary tumors
and lungs were harvested. Excised lungs were examined for grossly detectable
lesions.

Tissues were fixed in 10% neutral buffered formalin for 12-18 h. The samples
were stored in 70% ethanol, and then embedded in paraffin. Paraffin sections of
5µm were stained with hematoxylin and eosin. Mammary tumor histology and
lung metastasis were independently evaluated by two pathologists (Y.X and
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H.W). Immunohistochemistry (IHC) was performed as previously described (63).
Antibodies used are Ki67 (DAKO, Carpinteria, CA M7249), Tunel (Roche,
Indianapolis, IN), CD34 (eBioscience, San Diego, CA 14-0341), 14-3-3ζ (C-16,
Santa Cruz, Santa Cruz, CA sc-1019).SP-A (Santa Cruz sc-13977), AQP5
(Calbiochem, Germany 178615). For IHC analysis and quantification, 10 fields
were randomly chosen at 200X magnification. The total number of cells and
positive cells were counted and the average percentage of positive cells was
determined.

2.4 Immunoblotting
Tissues and mammary tumors were collected from mice. Protein extracts were
made by homogenizing samples in tissue lysis PBSTDS buffer [10 mmol/L
sodium phosphate (pH 7.3), 154 mmol/L NaCl, 5% sodium deoxycholate, 1%
SDS] using a tissue grinder, followed by centrifugation to remove particulate
matter and lipids. Immunoblotting was performed as previously described (63).
Antibodies used are anti-HA high affinity (clone 3F10, Roche 11867423001), 143-3ζ (C-16, Santa Cruz sc-1019), Neu (C-18, Santa Cruz sc-284), Erk (Cell
Signaling 4695), pErk (T202/Y204, Cell Signaling 4370), Mek1 (Cell Signaling
9126), pMek1 (S221, Cell Signal 2338), Akt (Cell signaling 9272), pAkt (S473,
Cell signaling 3787), p53 (DO-1, Santa Cruz sc-126), Bax (B-9, Santa Cruz sc7480), VEGF (A-20, Santa Cruz sc-152), PyMT(Novus Biologicals NB100-2749),
β-actin (Sigma A5441), α-tubulin (Sigma T5168), HIF1-α (Novus Biologicals
NB100-105) and IGF1R-β (Cell Signaling 3027)
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2.5 Quantitative RT-PCR for microRNA quantification

RNA of the tissue samples was retrieved using Trizol (Invitrogen, Carlsbad, CA)
following the standard protocol. Reverse transcription was performed using
Taqman MicroRNA Reverse Transcription kit ( Applied Biosystems 4366569)
and real time PCR was performed using Taqman Universal PCR Master Kit
(Applied Biosystems 4324018) and iQ SyBR Green Supermix (Bio-Rad 1708882). The specific primers and probe for miR-126 RT-PCR was purchased from
Applied Biosystems, 4427975-002228. The real time PCR was done on Bio-Rad
iCycler Real Time PCR machine. The primer sequences for CD31 are forward:
5’- CTGGTGCTCTATGCAAGCCT and reverse: 5’AGTTGCTGCCCATTCATCAC. The primer sequences for 18S ribosome protein
are forward: 5’- AACCCGTTGAACCCCATT and reverse: 5’CCATCCAATCGGTAGTAGCG.

2.6 Transwell migration assay
3x104 mouse endothelial cells resuspended in 500ul serum free medium were
seeded in the top chamber of the 24-well 8-um pore transwell plates. 600ul 10%
FBS containing medium was used as chemo-attractant in the bottom chamber.
The plates were incubated at 37C for 4 hours. The cells were fixed in 10%
neutral buffered formalin for 1 hour and stained with 0.5% crystal violet for 1
hour. The plates were flushed under tap water to remove excessive dye. The
cells that did not migrate were removed by cotton tips. Images were taken with
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Zeiss Discovery V20 microscope with equipped software. Quantification of the
migrated cells was performed using Adobe Photoshop and ImageJ software.

2.7 Tube formation assay
Matrigel (BD, Franklin Lakes, NJ 356231) was thawed at 4C overnight before
assay. 500ul matrigel was added into each well of the 24-well plate. The plates
were incubated at 37C 30 minutes to 1 hour to form gel. 3x105 cells
resuspended in 10% FBS containing DMEM/F-12 medium were plated above
the matrigel and incubated for 6 hours at 37C. Tube formation of the endothelial
cells was imaged with Olympus inverted fluorescence microscope and quantified
using ImageJ software.

2.8 Assessment of Proliferation, Apoptosis, and Angiogenesis
To assess proliferation rate or apoptosis, 1000 tumor cells were counted for the
percentage of Ki67 or TUNEL positive-staining cells by investigators blinded to
the identity of the mice. Angiogenesis was evaluated by CD34 IHC staining and
by counting blood vessels in three areas of the section at 200X magnification.
The blood vessel index was expressed as the mean number of vessels in the
three areas.

2.9 Growth Hormone Measurement

Blood samples were extracted through tail vein from 4 week old mice of both
sexes. Blood samples were placed on ice 2h to allow aggregation. Centrifuge
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the samples at 1500g for 10 minutes. Collect the top clear part of serum. Mouse
circulating growth hormone was measured using ELISA kit (Diagnostic Systems
Laboratories, Webster, TX DSL-10-72100) following the product instruction.

2.10 Circulating IGF-1 Measurement
Mouse circulating IGF-1 was measured using RIA kit (Diagnostic Systems
Laboratories DSL-2900) following the product manual.

2.11 Blood Glucose Measurement

A drop of blood was retrieved from a tail snip. Blood glucose level was
measured using Roche AccuChek Aviva blood glucose test system. Blood
drawing was performed ad libitum.

2.12 Glucose tolerance assay

Age matched mice with different genotypes were fasted for 16 hours. Roche
AccuChek Aviva blood glucose test system was used to measure blood glucose
level of the mice. Basal blood glucose was measured using the blood retrieved
from the tail snips and was set as time point of 0 minute. 3g/kg weigh of glucose
was injected intraperitoneally. Blood glucose was measured at the time points of
15, 30, 60 and 120minutes after injection.

2.13 Glucose uptake measurement
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Mice were injected (i.v.) 100 ul of 2-NBDG (50uM) and sacraficed 30 minutes
later. Their livers and brains were collected and imaged by Maestro Imaging
System (CRi Inc.) to measure 2-NBDG uptake in vivo. Fluorescence intensity
was measured using ImageJ software.

2.14 Statistical Analyses
Analysis of mammary tumor latency was performed using the Kaplan-Meier
method. Differences in survival were determined using log-rank test. Other
statistical differences were assessed with Student’s t-test or one-way ANOVA. A
P-value of <0.05 was considered statistically significant.
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Chapter 3 Results and Discussion

3.1 Generation of 14-3-3ζ
ζ knockout mouse

3.1a Generation of 14-3-3ζ
ζ mutant mouse strain
To systematically study the role of 14-3-3ζ in vivo, I generated a 14-3-3ζ
knockout mouse strain by gene trap. The cell line RRR334, in which 14-3-3ζ
was inactivated according to the 5’RACE data from Baygenomics database, was
obtained from the Mutant Mouse Regional Resource Center (MMRRC). We
confirmed silencing of 14-3-3ζ in the cell line by RT-PCR using a forward primer
homologous to exon 3 and a reverse primer homologous to β-geo cassette in
gene trap vector, pGT0Lxf, followed by sequencing the PCR product (Figure 4).
By designing multiple forward primers homologous to intron 3 and PCR
amplification along with a reverse primer homologous to gene trap vector, I
identified the exact integration site of the gene trap vector in 14-3-3ζ gene. The
first 152 base pairs (bp) of the gene trap vector were lost during integration. The
integration site of the gene trap vector was located about 3351bp downstream of
exon 3 as determined by PCR and sequencing the PCR product (Figure 5).
Southern blot was also designed and performed to confirm the genomic
integration. PCR genotyping primers were designed based on the integration
site (Figure 6). The ES cells were injected into C57Bl/6 albino mouse
blastocysts by the Genetic Engineered Mouse Facility (GEMF) at MD. Anderson
Cancer Center. Chimera mice with high ES cell contribution based on their fur
color were mated with C57Bl/6 albino mice to determine germ line transmission
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and obtain 14-3-3ζ knockout founder mice. Founder 14-3-3ζ heterozygous (+/-)
male with (+/-) female mice were mated to generate 14-3-3ζ homozygous (-/-)
mutant mice.
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Figure 4. RT-PCR confirmation that the ES cell line RRR334 had 14-33ζ inactivated. Schematic view of that the gene trap vector integrated into the
intron 3 of 14-3-3ζ gene. Ywhaz is the HUGO Gene Nomenclature Committee
approved gene symbol for 14-3-3ζ. The line indicates the introns for 14-3-3ζ
gene, whereas the rectangles indicate the exons. The solid parts indicate the
coding region for 14-3-3ζ protein. The gene trap vector pGT0Lxf was integrated
~3.3kb downstream of exon 3. SA is short for the splice acceptor sequence of
mouse En2 exon 2. β-Geo/pA indicates the fusion of β-galactosidase and
neomycin transferase followed by SV40 polyadenylation signal. The arrows
indicate the primers for RT-PCR. The scale bar is for 1kb length of DNA
sequence. The endogenous 14-3-3ζ is expressed both in wild type ES cell
control, TC1 and the mutant cell line RRR334. The exogenous mutant allele only
exists in the RRR334 cell line.
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Figure 5. Determination of the gene trap vector integration site in 14-3-3ζ
genome using PCR. The integration of the gene trap vector into 14-3-3ζ
gene is described earlier. The arrows indicate the primer for PCR. The
numbers on each lane of the gel indicate the primer position in the 14-33ζ gene. “N” is for negative control and “M” is for marker. The 1636bp and
506bp maker sizes are shown.
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Figure 6. Genotyping of 14-3-3ζ mutant mouse. A. schematic view of the
integration of the gene trap vector into 14-3-3ζ gene as described earlier.
Arrow heads indicate the primers for genotyping. B. Representative data of
PCR genotyping of 14-3-3ζ wild type (+/+), heterozygous (+/-) and
homozygous mutant (-/-) mouse. “M” is for DNA marker. 1kb and 0.5kb
DNA fragments were indicated as shown. Wild type allele generated a
954bp band and the mutant allele generated a 544bp PCR product.
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3.1b This mouse strain is a strong hypomorphic mutant model for 14-3-3ζ
ζ
14-3-3ζ expression was significantly inhibited in multiple tissue types from the
knockout mice, especially in mammary gland to our interest (Figure 7). As the
exon 3 which encodes the first 98 amino acid was expected to be expressed as
a fusion protein followed by the β-geo cassette, I tested whether the N-terminal
part of 14-3-3ζ protein had any function. We transfected the HA-tagged Nterminal 145 amino acids of 14-3-3ζ which encodes a shortened 14-3-3ζ form
lacking the C-terminal target binding groove structure (29, 30) and should be
similar with the N-terminal 98aa 14-3-3ζ fragment in term of structure, into MCF7
cells. I found that the protein was barely detectable by western blot using HA
antibody. Only when the cells were treated with the proteasome inhibitor MG132
could we detect the expression of the HA tagged protein. I could not detect the
14-3-3ζ/β-geo fusion protein in mouse tissues by western blot using either 14-33ζ or β-gal antibody. There was no difference in proliferation as determined by
MTT assay. The activation of Ras/Raf/Erk and PI3K/Akt signaling, as indicated
by phosphorylated Mek1 and Akt, which could be activated by overexpression of
14-3-3ζ (12, 88), were not affected (Figure 8). It is also reported that C-terminal
deleted 14-3-3 could not bind to hTERT and promote its nuclear translocation
(89). Based on these, I conclude that the N-terminal part of 14-3-3ζ is not
functional probably due to its rapid degradation. Considering all these data, this
mouse strain is a strong hypomorphic mutant model in which we can study the
role of 14-3-3ζ in vivo.
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Figure 7. 14-3-3ζ is significantly downregulated in homozygous mutant
mouse mammary gland. A. Western blot to detect 14-3-3ζ expression in
wild type (+/+), heterozygous mutant (+/-) and homozygous mutant (-/-)
mouse mammary gland. β-actin was used as loading control. B.
Quantification of 14-3-3ζ expression in different genotyping mice tissues
from 3 independent experiments.
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Figure 8. 14-3-3ζ N-terminal fragment is non-functional. A. 14-3-3ζ N-terminal
fragment was not stable. Western blot of lysate from MCF7 transfected with
vector control (Vc) and 2 HA-tagged delta-C-terminal fragment of 14-3-3ζ
transfected cell lines (dC1 and dC12) treated with DMSO or 50nM MG132 for
4 hours. Endogenous 14-3-3ζ was detected using 14-3-3ζ antibody while the
exogenous 14-3-3ζ fragment was detected using HA antibody. β-actin was
used as loading control. B. 14-3-3ζ N-terminal fragment did not affect
proliferation in MCF-7 cells suggested by MTT assay. OD was measure at
570nm and normalized to 650nm. C. 14-3-3ζ N-terminal fragment did not
activate Mek1 and Akt indicated by their phosphorylation status. β-actin was
used as loading control
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3.1c Discussion
The strategy I used to knockout 14-3-3ζ was gene trap. Gene trap is a highthroughput method to inactivate specific gene expression by introducing
insertional mutations genome wide. In addition to the traditional loss of function
mutant alleles introduced, recently developed gene trap vector also allowed a
variety of post-insertional modification strategies for the generation of other
experimental alleles. It is a very valuable resource for the research community to
study specific gene function in vivo. For more details about how gene trap
works, one can go to the International Gene Trap Consortium at www.igtc.org for
more information.
Despite of all the advantages gene trap provides, it has intrinsic limitation and
pitfalls as well. I had two concerns. First, gene trap utilized strong splicing
acceptor site to make alternative RNA splicing product in competition to the
endogenous gene. It is highly possible that the endogenous gene was still
expressed at certain extent. The dosage of the leakage may be critical for any
phenotype I would observe. Secondly, gene trap of the host gene will result in a
fused mRNA product composed of the exons in front of the gene trap insertion
site and the β-geo cassette. If the exons encode protein sequences, it is
necessary to confirm that part of the protein is not functional. Any retain of
function, gain of function, dominant negative would interfere the interpretation of
the data we generate from the mouse.
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Here I experimentally showed that endogenous 14-3-3ζ expression is
significantly downregulated in the knockout mouse tissues and the N-terminal
part of 14-3-3ζ is not functional. Only ~5% 14-3-3ζ was expressed compared to
the wild type mouse tissues. The remaining 14-3-3ζ protein probably cannot play
full function as that in the wild type mouse tissues. With these data in hand, I can
be confident to move on to test the phenotype mediated by loss of 14-3-3ζ.
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3.2 14-3-3ζ
ζ knockout mice are lethal neonatally
3.2a 14-3-3ζ
ζ mutant mice are lethal neonatally in C57Bl/6 genetic
background
An interesting phenotype was observed after mating the founder mice and that is
only about 5% of the offspring generated from mating heterozygous male and
female founders were 14-3-3ζ homozygous mutant mice as determined by PCR
genotyping 10 days after birth (table 1). This indicates that 14-3-3ζ knockout
mice may be lethal during embryo development or quickly after birth.
As about 5% homozygous mice survived, the genetic background is likely to play
important role mediating the lethality phenotype. To test this, I backcrossed the
mutant to strain into congenic C57Bl/6 genetic background determined by
genome scan using a panel of simple sequence length polymorphisms (SSLP)
(microsatellites) markers. No homozygous mutant pups were found at the time
of genotyping 10 days after birth (table 1), which confirmed the lethality
phenotype we observed in B6/129P2 hybrid genetic background. The lethality is
even more severe in this genetic background. To determine the time point when
the 14-3-3ζ knockout embryos die, we dissected the embryos at 18.5dpc. We
observed that the ratio of the knockout embryos matched the Mendellian
Inheritance Law, which indicated that the 14-3-3ζ knockout embryos were alive
at this time point (table 1). In contrast to that the wild type and heterozygous
embryos that started to breathe, became red and survived after dissection, the
knockout embryos got pale and died quickly after dissection after several
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attempts to breathe. Similar phenomenon was observed in new born mice,
which suggested that the 14-3-3ζ knockout mice are lethal neonatally in C57Bl/6
genetic background.
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Strain/genotype

+/+

+/-

-/-

P-value

B6/129P2 F2

22

39

3

0.0052**

B6 congenic

58

72

0

<0.0001***

B6-18.5dpc

16

32

15

0.9879

CD-1

36

73

38

0.9849

Table 1. 14-3-3ζ knockout mouse are lethal neonatally in C57Bl/6 genetic
background and are viable in CD-1 background. Genotyping of pups generated
from mating heterozygous breeders was performed 10 days after birth.
Genotyping of the embryos were dissected at 18.5dpc (days postcoitus). B6
indicates the C57Bl/6 strain. 129P2 was previously name as 129/OlaHsd in
which background the ES cells were originally generated.
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3.2b 14-3-3ζ
ζ mutant pups die due to respiratory failure
All the 14-3-3ζ knockout embryos die within 0.5 hour after dissection indicating
that they may die from breathing distress (90). To test this, we dissected the
lungs of the embryos. In contrast to the wild type lungs which floated in water,
the knockout lungs sank, suggesting no air got into the lungs. The same
phenomenon was also observed in new born knockout pups. So it is concluded
that the 14-3-3ζ knockout mice are lethal neonatally due to respiratory failure.
H&E staining of the lung section indicated that the knockout mice had defects in
lung development and was stuck at the pseudoglandular stage. The lungs
lacked saccular structure and had increased mesenchymal compartment and
thickened saccular septae (Figure 9). To better understand the pathology in the
knockout lungs, we performed immunohistochemistry staining on the lung
sections. There was no difference in proliferation as determined by Ki67, type I
and type II pneumocyte differentiation determined by pulmonary surfactantassociated protein A (SP-A) and Aquaporin isoform 5 (AQP5) staining(Figure
10). Interestingly, we found that the blood vessels in the knockout lungs were
not integrated. Around the vessels, there were aggregations of leukocytes.
Meanwhile there were increased blood cells in the knockout lung section
compared to the wild type counterparts. These data suggest that defects in
angiogenesis play an important role mediating the breathing distress in the
knockout mice (Figure 11).
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Figure 9. 14-3-3ζ knockout mice had defect in lung development. Hemotoxylin
and Eosin staining was performed on lung tissue dissected from 18.5dpc
embryos. The wild type lungs were inflated and had saccular structure. The 143-3ζ knockout lungs were deflated, lack saccular structure and had thickened
septae, increased mesenchymal compartment and more blood cells spread in
the lung tissues. Scale bar indicates 50um in length
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Figure 10. 14-3-3ζ did not affect proliferation and pneumocytes differentiation.
Immunohistochemical staining of proliferation marker Ki67, type I pneumocyte
marker SP-A and the type II pneumocyte marker AQP5 were performed on lung
tissue sections from wild type (+/+) and 14-3-3ζ homozygous mutant (-/-)
18.5dpc embryos. Scale bar indicates 200um in length.
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CD34

+/+

-/-

Figure 11. Loss of 14-3-3ζ lead to angiogenesis defect in lungs. Blood vessel
endothelial cell marker CD-34 was stained immunohistochemically on 18.5dpc
embryos lungs. 14-3-3ζ knockout lungs had leaky bid blood vessels and fewer
peripheral blood vessels. Aggregation of leukocytes was present around the
broken vessels in 14-3-3ζ knockout lungs. Scale bar indicates 200um in length.
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3.2c microRNA-126 is downregulated in 14-3-3ζ
ζ knockout lungs
To understand the key molecular mechanism mediating respiratory
distress, I searched the Mouse Genome Infomatics (MGI) database on the
Jackson Laboratory using key word “lethal”, “respiratory” and “angiogenesis”.
More than 100 genes popped out, among which a lot are 14-3-3ζ binding
proteins like TgfβRI, β-catenin. Interestingly, microRNA-126 is the only
microRNA in the list.
MiR-126 is an endothelial specific microRNA that regulates vascular integrity
and angiogenesis (76-78).Targeted deletion of miR-126 resulted in lethality and
lung deflation due to vascular abnormalities. The angiogenic signaling was
significantly diminished in the knockout tissues and resulted in defective
endothelial sprouting, adhesion and growth (76). MiR-126 was upregulated by ~
3 fold in our 14-3-3ζ overexpression cell line compared to the vector control cell
line as determined by a microRNA microarray.
I extracted RNA from the lung tissue and performed real-time quantitative
reverse-transcript polymerase-chain reaction (qRT-PCR) and found that the
miR-126 level was significantly downregulated in the 14-3-3ζ knockout lungs
comparing to the wild type counterparts (Figure 12).
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*

Figure 12. MicroRNA-126 was downregulated in 14-3-3ζ knockout lungs. Total
RNA was extracted from 18.5dpc lung tissues from wild type (+/+) and 14-3-3ζ
knockout (-/-) embryos. MiR-126 expression level was determined by
quantitative real-time RT-PCR normalized to PECAM1 mRNA level.
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3.2d Discussion
Here I observed the neonatal lethality in 14-3-3ζ knockout mouse under C57Bl/6
genetic background.
Genetic background apparently play important role mediating this phenotype, as
several 14-3-3ζ knockout mice survived at the time of genotyping which is 10
days after birth. Combining with the data later in part 3.3, the knockout mice are
completely viable and fertile in CD-1 and FVB/N genetic background. One
possible reason may be that different strains have different alternative splicing
capability. The 14-3-3ζ expression level may be much lower in the B6 genetic
background. My data did not support this view. The expression level of 14-3-3ζ
remained low in all the genetic background. This leads to another possible
explanation that 1 or more C57Bl/6 specific mutations in addition to loss of 14-33ζ resulted in the lethality. It will be interesting to study which genes they are. If
someone is to develop 14-3-3z targeting therapy for patients, it is important to
identify and exclude those patients bearing such mutation from the therapy to
prevent severe side effects.
MiR-126 downregulation correlated with the 14-3-3ζ loss mediated lethality.
However, miR-126 was only downregualted about half in 14-3-3ζ knockout mice
lungs. MiR-126 heterozygous mutant mice were viable and fertile. Also 14-3-3ζ
knockout mouse did not completely phenocopy the miR-126 knockout mouse.
So downregulation of miR-126 is not the only mechanism underlying the
respiratory failure phenotype mediated with defective angiogenesis. MiR-126
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downregulation in addition to global signaling deregulation finally lead to this
phenotype. Many other molecules like those mediating TGF-β signaling,
Ras/Raf/Erk and PI3K/Akt signaling could also mediate this phenotype. I
recently found that loss of 14-3-3ζ resulted in reduced HIF1-α, a well known
oncogene that promotes angiogenesis by transcriptionally activate VEGF in
multiple tissue types. It will be interesting to further study the how loss of 14-3-3ζ
lead to neonatal lethality. Measuring the HIF1-α expression in the embryo lungs
may help us gain more function.
It will also be interesting to study whether miR-126 downregulation is playing a
causal role in the lethality phenotype. I can either cross the 14-3-3z knockout
mouse to miR-126 transgenic mouse and test whether ectopically expressing
miR-126 could rescue the phenotype.
MicroRNAs are able to target multiple mRNAs to regulate cellular processes.
Many miR-126 targets have been reported to date. Spred-1 which is a
suppressor of Ras/Raf/Erk signaling in response to VEGF stimulation is inhibited
by miR-126 (76). VCAM1, which is a cell surface adhesion molecule, was
upregulated in response to TNF-α stimulation when miR-126 is knocked down.
Overexpression of VCAM1 resulted in more leukocyte adhesion to endothelial
cells (91). This data matched my observation that more leukocytes are visible in
the 14-3-3ζ knockout embryo lungs especially around the blood vessels. In the
future, it will be interesting to determine the expression level of the miR-126
targeting genes and test how important miR-126 is in this lethality phenotype.
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3.3 Loss of 14-3-3ζ
ζ inhibited mammary gland tumor formation and lung
metastasis
3.3a Outbreeding rescues the lethality
The lethality hindered our study of 14-3-3ζ role in adulthood diseases like
cancer. As we found a proportion of homozygous mutant pups could survive the
lethality in B6/129P2 hybrid genetic background, it is likely that outbreeding may
circumvent the lethality phenotype. To test this, I outbred the 14-3-3ζ knockout
strain to CD-1. Approximately 25% of homozygous mutant pups were generated
by mating heterozygous males and females after outbreeding (table 1), which
indicated that the outbreeding rescued the neonatal lethality. The 14-3-3ζ
knockout mice could also breed without any obvious defect. At the same time, I
also backcrossed the strain to FVB/N congenic background. The 14-3-3ζ
knockout mice under FVB/N genetic background were also viable and fertile.
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3.3b Loss of 14-3-3ζ
ζ did not significantly affect mammary gland
development
In our initial attempt to study the role of 14-3-3ζ in breast cancer, we first
examined the mammary gland development in 14-3-3ζ knockout mice.
Mammary glands were dissected from the mice at 4, 6, 8 and 12 weeks of age
by biopsy. We performed whole mount staining of the mammary gland and
found that the mammary gland parenchyma outgrowth was slightly delayed at 4
and 6 weeks of age in the knockout mice. The epithelial parenchyma in the wild
type mammary gland exceeded the lymph node in contrast to that in the 14-3-3ζ
knockout mice barely touched the lymph node at 4 week of age. At the age of 8
weeks, the outgrowth of the duct was restored to that in the wild type mice
(Figure 13). The 14-3-3ζ knockout female mice could breed and nurse the pups,
which also suggested that the 14-3-3ζ knockout mammary glands were
biologically functional.
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Figure 13. Loss of 14-3-3ζ did not significantly affect mammary gland
development. The fourth mammary glands from the left side of the mice were
dissected at the time points of 4, 6, 8 and week of age as indicated. Whole
mount staining was performed to determine the epithelial parenchyma outgrowth
and branching. Scale bar indicates 5mm in length.
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3.3c Loss of 14-3-3ζ
ζ inhibited mammary gland tumor formation and
metastasis induced by PyMT
To study the role of 14-3-3ζ in breast cancer, we crossed the 14-3-3ζ
knockout mouse strain with MMTV promoter driven Polyoma middle T antigen
(PyMT) transgenic strain which develops mammary gland tumor at an early age.
The 14-3-3ζ knockout mice had significantly longer latency of tumor onset. The
mice were sacrificed when the tumor diameter reached 15 mm. The tumors were
harvested for further study. Histological study of the tumor suggested that loss of
14-3-3z did not affect the tumor subtype. The tumors from both wild type and 143-3z knockout mice are invasive adenocarcinomas. The lungs were dissected to
determine the number of lung metastases by visually counting the surface tumor
nodules. The 14-3-3ζ knockout mice had significantly lower number of lung
metastases nodules (Figure 14).
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Figure 14. Loss of 14-3-3ζ inhibited tumorigenesis and lung metastasis. A. 14-33ζ homozygous mutant mice (-/-, n=8) had significantly longer tumor latency
induced by PyMT compared to the wild type (+/+, n=10) and heterozygous
mutant (+/-, n=17) counterparts. B. 14-3-3ζ homozygous mutant mice had
reduced lung metastasis as determined by surface tumor nodule number. ***
indicates P value < 0.0001.
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3.3d 14-3-3ζ
ζ knockout tumors express lower 14-3-3ζ
ζ level
Because the gene trap inactivates the expression of 14-3-3ζ by utilizing the
transcription splicing machinery, it is possible that the tumors in the knockout
mice may arise from single cells that express comparable level of 14-3-3ζ as
that in wild type cells. We performed both western blot (Figure 17) and
immunohistochemical staining on the tumors (Figure 15). We found that the
tumors from the knockout mice expressed much lower level of 14-3-3ζ
compared to the tumors araised from the 14-3-3ζ wild type mice. This suggested
that the tumors from the knockout mice did not arise from cancer initiating cells
expressing high level of 14-3-3ζ . This data also suggested that knockdown of
14-3-3ζ was not sufficient to completely inhibit PyMT oncogene induced tumor
formation. To cure cancer expressing high level of 14-3-3ζ need combination of
other therapy regimen with 14-3-3ζ target therapy.
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Figure 15. 14-3-3ζ expression is downregulated in the tumors from homozygous
mutant mice. A. Immunohistochemical staining of 14-3-3ζ was performed on
tumor tissues from the mice. B. Quantification was performed using the IRS
scoring system from 0-3 with 0 indicating no expression and 3 indicating the
highest expression of 14-3-3ζ. 14-3-3ζ expression was significantly lower in the
knockout tumors.
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3.3e Loss of 14-3-3ζ
ζ affected multiple aspects in tumor biology by
regulating multiple signaling pathways
Next I studied how loss of 14-3-3ζ resulted in inhibited tumor formation and
metastasis. By staining the tumor slides with proliferation marker Ki67, apoptosis
marker TUNEL, and angiogenesis marker CD34, I found that the 14-3-3ζ
knockout tumors had reduced proliferation, increased apoptosis and reduced
angiogenesis compared to their wild type counterparts (Figure 16).
To study the molecular mechanism underlying these biological changes in the
14-3-3ζ knockout tumors, I started with a reverse phase protein array (RPPA)
assay performed in the Functional Proteomics Reverse Phase Protein Array
Facility at MD Anderson Cancer Center, which contained about 135 antibodies
to determine what molecules were deregulated in 14-3-3ζ knockout tumors. Two
signaling pathways could be activated downstream of PyMT and those are the
Ras/Raf/Erk and PI3K/Akt signaling pathways. , Both the signaling pathways
were significantly inhibited in the knockout tumors as indicated by phospho-RafS388, phospho-Mek1-S217, phospho-Akt-T308 and phospho-Akt-S473 (Figure
17A).This finding was further validated by western blot. I found that phosphoErk1/2-T202/Y204 and phospho-Akt-S473 was downregulated in the knockout
tumors indicating the Ras/Raf/Erk and PI3K/Akt signaling pathways were
inhibited in knockout tumors. I also found that the well known tumor suppressor
p53 was upregulated in the knockout tumors. These data matched the previous
reports that 14-3-3ζ overexpression activated Akt and hence suppressed p53 via
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phosphorylation-dependant activation of Mdm2 (69). Two molecules
downstream of p53, the pro-apoptotic protein Bax which is transcriptionally
activated by p53 was upregulated, whereas the pro-angiogenic protein VEGF
transcriptionally suppressed by p53 was significantly downregulated. These data
at least partially explained the reduced proliferation, angiogenesis and increased
apoptosis as observed in knockout tumors (Figure 17B).
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Figure 16. Loss of 14-3-3ζ affected multiple aspects of cancer biology. A.
Proliferation marker Ki67 was immunohistochemically staining in the tumor
samples and quantified. Ki67 index indicates the percentage of Ki67 positive
cells in 10 randomly selected fields. Scale bar indicates 50um in length. B.
Immunohistochemical staining of apoptosis marker Tunel and quantification.
Tunel index indicates the Tunel positive cells in 10 randomly selected high
power fields. Scale bar indicates 200um in length. C. immunohistochemical
staining of angiogenesis marker CD34 and quantification. CD34+ index indicates
blood vessel numbers in 10 randomly selected fields. Scale bar indicates
100umin length. Quantification data are presented as mean ± standard error or
the mean. ** indicates P-value <0.01, *** indicate P-value<0.0001.
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Figure 17. Loss of 14-3-3ζ affected multiple signaling molecules expression. A.
Heat map of reverse phase protein array results comparing the gene expression
profiles in wild type and 14-3-3ζ homozygous mutant tumors. Clustering was
calculated using software Cluster 3.0 and the heat map was generated using
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JAVA tree. B. Western blot results confirmed that inactivation of Ras/Raf/Erk
and PI3K/Akt in the 14-3-3ζ knockout tumors as determined by p-Erk and p-Akt.
Total Erk and Akt were blotted as control and β-actin was used as loading
control. 14-3-3ζ was blotted to confirm that 14-3-3ζ expression was inhibited in
the 14-3-3ζ homozygous mutant tumors.
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3.3f loss of 14-3-3ζ
ζ inhibited tumorigenesis induced by Neu oncogene
Interestingly, we also found that PyMT expression level was also reduced 14-33ζ knockout tumors (Figure 17). PyMT could bind to 14-3-3ζ when
phosphorylated on serine 257(23). S257 mutated PyMT inhibited salivary gland
tumor formation compared to wild type viral antigen (92). To rule out the
possibility that the inhibited tumor formation and metastasis was due to
downregulated expression of PyMT mediated by loss of 14-3-3ζ, we crossed the
14-3-3ζ knockout strain with MMTV driven activated Neu (NDL 2-5) transgenic
mouse strain. The 14-3-3ζ knockout mice also exhibited delayed tumor onset
induced by Neu (Figure 18), whereas the expression level of ErbB2 was not
downregulated as determined by western blot (Figure 19). Immunohistochemical
analysis confirmed that the 14-3-3ζ knockout lead to reduced proliferation,
angiogenesis and increased apoptosis (Figure 20). These data suggested that
inhibition of tumor formation and metastasis is not due to downregulation of
PyMT in the 14-3-3ζ knockout mice but to the loss of 14-3-3ζ mediated global
signaling deregulation. So loss of 14-3-3ζ could inhibit tumor formation in two
different tumor prone mouse models.
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Figure 18. Loss of 14-3-3ζ prolonged tumor latency induced neu oncogene.
Kaplan-Meyer curve study of the percentage of tumor free mice along with the
age of the neu transgenic mice is diagramed. P-value is indicated as shown.
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Figure 19. Neu oncogene expression was not affected in 14-3-3ζ knockout
tumors. Western blot of Neu in 14-3-3ζ wild type and homozygous mutant
tumors induced by neu oncogene. GAPDH was used as loading control.
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Figure 20. Loss of 14-3-3ζ affects tumor biology in Neu oncogene induced
tumors. A. Immunohistochemical staining of proliferation marker Ki67 and
quantification. Ki67 index was calculated as percentage of Ki67 positive cells in
10 randomly selected fields. B. Immunohistochemical staining of apoptosis
marker caspase 3 and quantification as average caspase 3 positive cell
numbers every high power field (hpf) from 10 randomly selected fields. C.
Immunohistochemical staining of angiogenesis marker CD34 and quanfication.
CD34+ index indicates the average blood vessel number per hpf from 10
randomly selected fields. Scale bar indicates 200um in length. Quantification
data presented as mean± standard error of the mean. * indicates P-value<0.05,
** indicates P-value<0.01 and *** indicates P-value<0.001.
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3.3g miR-126 is downregulated in 14-3-3ζ
ζ knockout tumors
I previously found that microRNA-126 was along with defective
angiogenesis downregulated in 14-3-3ζ knockout lung tissues. Angiogenesis
was also reduced in 14-3-3ζ knockout tumors. In my initial test whether miR-126
was also an important mediator of defective angiogenesis induced by loss of 143-3ζ in tumors, I used quantitative real-time RT-PCR to measure miR-126
expression level in the tumor samples and found that miR-126 was significantly
downregulated in 14-3-3ζ knockout tumors (Figure 21).
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Figure 21. MicroRNA-126 was downregulated in 14-3-3ζ knockout tumors. Total
RNA was extracted from wild type and 14-3-3ζ knockout tumor tissues induced
by PyMT. qRT-PCR of miR-126 was perfomed and normalized to
PECAM1/CD31.Fold change of miR-126/CD31 ratio is presented as mean ±
standard error of the mean. ** indicates P-value < 0.01.
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3.3h miR-126 regulates angiogenesis downstream of 14-3-3ζ
ζ
To further test whether miR-126 was one of the key players in the
angiogenesis defect mediated by loss of 14-3-3ζ. First of all, I transfected the
mouse endothelial cell line with scramble or 14-3-3ζ shRNA and found that
knocking down 14-3-3ζ significantly inhibited the angiogenic capability of the
mouse endothelial cells as determined by transwell migration assay and tube
formation assay (Figure 22). This in vitro result supported the in vivo finding that
14-3-3ζ was critical in angiogenesis both in embryo lungs and tumors. When I
transfected the 14-3-3ζ knockout down cells with pre-miR-126, the angiogenic
capability was restored (Figure 22). These data suggested that miR-126 was a
key regulator of angiogenesis downstream of 14-3-3ζ.
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Figure 22. microRNA-126 regulates angiogenesis downstream of 14-3-3ζ. A.
Mouse endothelial cells were transfected with scramble or 2 independent 14-33ζ shRNAs. 14-3-3ζ knockdown efficiency was determined by western blot. βactin was used as loading control. B. Image of the transwell migration assay and
quantification. Cells transfected with scamble or 14-3-3ζ shRNA in combination
with control pre-microRNA or pre-miR-126 were tested for the migration
capability. Migrated cells were stained with crystal violet, imaged and quantified
with ImageJ. Data presented as mean ± standard error of the mean. C. Image of
the tube formation assay and quantification. The cells were seeded on matrigel
and cultured in incubator for 4-12 hours and imaged. Tube formation capability
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was determined by the average length of the tube structure formed every high
power field. Assays were repeated 3 times. Data presented as mean ± standard
error of the mean.
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3.3i Discussion
14-3-3ζ has been considered a potential oncogene and therapy target.
Here we found that loss of 14-3-3ζ significantly inhibited tumorigenesis,
progression and lung metastasis in two different tumor prone mouse models.
Hundreds of proteins have been reported to form complexes with 14-3-3ζ.
It was not a surprising to see in the RPPA analysis that many genes expression
are differential between the wild type and 14-3-3ζ knockout tumors. With the
global signaling deregulation, I can easily explain the tumor biology change such
as reduced proliferation, increased apoptosis and reduced angiogenesis in the
14-3-3ζ knockout tumors. This inhibited tumorigenesis and lung metastasis
suggested to me that 14-3-3ζ can be a potential therapy target. Though
knocking down of 14-3-3ζ alone could not completely inhibit tumor formation or
cure tumor, one can try treating the mice with chemo- or redioacitve therapeutic
regimens and test the potential of combinational therapy. As in clinic many
targeted therapies are used in combination with chemotherapy, it is possible that
combinational therapy could cure the tumor.
MicroRNA-126 has been shown to be downregulated in 14-3-3ζ knockout
embryo lungs. Here miR-126 is also downregulated along with reduced
angiogenesis in 14-3-3ζ knockout tumors suggesting miR-126 regulation by 143-3ζ is a conserved signaling both in lung development and tumor progression.
MiR-126 role in cancer remains controversial. Some published papers argue that
miR-126 functions as a tumor suppressor in breast cancer (84, 93, 94). It was
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hypothesized that downregulation of miR-126 could result in leaky blood vessel
and thus enhancing metastasis. However, these studies were performed using
epithelial cell lines or the whole tumor in which epithelial cells were the major
compartment, whereas miR-126 expression was restricted in endothelial cells.
So it would be reasonable to normalize the miR-126 expression level to
endothelial specific housekeeping gene. As I mentioned, I used PECAM1 as
control in this study. How miR-126 functions in cancer remains to be further
studied.
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3.4 14-3-3ζ
ζ knockout mice are growth retarded
3.4a 14-3-3ζ
ζ knockout mice are smaller than their littermates
Interestingly, except the inhibited tumor formation and progression, I also
observed that the 14-3-3ζ knockout mice are smaller than their wild type and
heterozygous littermates after outbreeding (Figure 23). They weigh less than
their wild type counterparts since 2 week of age. The difference got most
significant at 3 and 4 week of age. Then the knockout mice could catch up to
some extent later (Figure 23). Because the time matched the puberty onset in
mice, this data suggested that the14-3-3ζ knockout mice seemed to be smaller
and have late onset of puberty and are growth retarded.
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Figure 23. 14-3-3ζ knockout mice are growth retarded. A. Image of the 14-3-3ζ
wild type (wt), heterozygous (het) and homozygous mutant (homo) mice on the
weaning date which is 3 week of age. Top panel image was taken on male mice
in one litter and bottom panel was taken on female mice from one litter. B.
Mouse weight along with the age. Weigh data gram (g) were obtained from 2 to
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8 week (wk) of age from wild type and homozygous mutant mice presented as
mean ± standard error of the mean. * indicates P-value<0.05, ** indicates Pvalue<0.01 and *** indicates P-value<0.0001.
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3.4b 14-3-3ζ
ζ knockout mice had reduced growth hormone but increased
IGF-1 in circulation
As the most significant difference in weight between wild type and the
knockout mice was observed at the age around 3-4 weeks which matched the
puberty onset in mice, it suggested that 14-3-3ζ had impact on puberty onset in
mouse. Growth hormone and insulin-like growth factors are well documented to
regulate pubertal growth (95-98). I measured circulating growth hormone and
IGF-1 to start with. Interestingly, compared to the reduced growth hormone level
in the knockout mice circulation as I expected, the serum IGF-1 level was
significantly increased in the knockout mice blood (Figure 24).
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Figure 24. Loss of 14-3-3ζ lead to aberrance in growth related hormonal
expression. A. Serum samples were drawn from 4 week old mice tail vein.
Growth hormone level was measure using ELISA following standard protocol. B.
Active IGF-1 level was measured using RIA kit following the product instruction.
Sample size of each group was indicated in the figure. ** indicates P-value<0.01
and *** indicates P-value< 0.0001.
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3.4c 14-3-3ζ
ζ knockout mice had aberrant glucose homeostasis
As I observed the increased IGF-1 in the 14-3-3ζ knockout mouse
circulation in contrast to our expectation, and IGF-1 and its receptors play critical
role in regulating growth and glucose homeostasis, I tested whether there was
any aberrance in glucose homeostasis in the 14-3-3ζ knockout mice.
Interestingly, I found that the blood glucose level in the knockout mice was
significantly lower than that of the wild type mice (Figure 25). As IGF-1 promotes
glucose uptake and regulates glucose homeostasis (99, 100), this data matched
the observation of increased IGF-1 level in the 14-3-3ζ knockout serum.
However, interestingly, loss of 14-3-3ζ inhibited Akt activation observed in
multiple studies including the tumorigenesis study induced by PyMT as
previously described in this dissertation. Akt promotes glucose uptake by
regulating multiple signaling pathways (101). Next I did glucose tolerance assay
to better understand how 14-3-3ζ impacts glucose homeostasis. Remarkably, I
found that though the basal blood glucose level was lower in the 14-3-3ζ
knockout mice after 16 hour fasting, after glucose challenge, the glucose
clearance from the blood was much slower in the knockout mice compared to
the wild type counterparts. This data suggested that the glucose uptake was
inhibited in the 14-3-3ζ knockout mouse tissues. To test this, I injected the mice
with a fluorescent glucose homolog, 2-NBDG into the mice via i.v., harvested the
brain and liver tissues which are the tissues uptake majority of glucose from
circulation and measured the glucose uptake level indicated by 2-NBDG
fluorescence intensity. I found the 2-NBDG level in the 14-3-3ζ knockout mice
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brain and liver tissues was much lower than that in the wild type tissue (Figure
26).
Based on these data, I conclude that 14-3-3ζ affected glucose
homeostasis.
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**

Figure 25. Loss of resulted in lower blood glucose. A drop of blood was drawn
from mouse tail snip ad libitum. Blood glucose was measure using Roche
AccuChek blood glucose meter. Sample size was indicated as shown. **
indicates P-value<0.01.
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Figure 26. 14-3-3ζ regulates glucose uptake. A. 14
14-3-3ζ null mice had impaired
glucose tolerance. Age matched 14
14-3-3ζ wild type (wt) and knockout (homo)
mice were fasted 16 hours. 3g/kg weigh glucose was injected intraperitoneally.
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Blood glucose was measured using blood retrieved from the tail snips at the time
points indicated in the figure. * and *** indicated that the blood glucose levels
were statistically significantly different between the groups. (*, P<0.05; ***,
P<0.001). B. Representative images of 2-NBDG fluorescent signal in 14-3-3ζ
wild type and 14-3-3ζ knockout mouse brain visualized by the Maestro system.
Fold change of 2-NBDG signal intensity quantified by Image J software. Data
presented as mean ± standard error of the mean. * indicates statistical Pvalue<0.05.
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3.4d molecular mechanism underlying the defective glucose homeostasis
Then I wondered what was the molecular mechanism mediating the
reduced glucose uptake. HIF1-α and IGF1R caught my attention. HIF1α, hypoxia induced factor 1 alpha, is a well known transcription factor that
regulates glucose homeostasis, angiogenesis and cell survival by
transcriptionally activate PGK1, LDH1, Glut1 and other hypoxia responsive
genes like VEGF (102, 103). 14-3-3ζ overexpression activates Akt (69), which is
also involved in reprogramming of metabolic genes. Additionally, activation of
mTOR, downstream of Akt, could lead to activation of HIF1-α that could drive
the major cancer metabolic changes (104). IGF1R activates PI3K/Akt signaling
pathway and can regulates glucose homeostasis (105). Loss of IGF1R resulted
in neonatal lethality due to respiratory failure and severe dwarfism (106). I
measured the expression level of HIF1-α in mouse mammary gland and IGF1R
in mouse embryonic fibroblast (MEF) cells. I found that HIF1-α and IGF1R
expression level was significantly downregulated in 14-3-3ζ knockouts (Figure
27). So HIF1-α and IGF1R can be regulated by 14-3-3ζ to maintain glucose
homeostasis.
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Figure 27. 14-3-3ζ regulates HIF1-α and IGF1R. A. Loss of 14-3-3ζ
downregualted HIF1-α. Protein lysates extracted from mammary glands of wild
type (+/+) and knockout (-/-) mice. B. Loss of 14-3-3ζ downregulated IGF1R.
Protein lysate extracted from immortalized mouse embryonic fibroblast (MEF)
cells generated from wild type (+/+), heterozygous (+/-) and 14-3-3ζ
homozygous knockout (-/-) mouse embryos.
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3.4e Discussion
Growth hormone/Igf-1 axis signaling has been reported to regulated mammary
gland development (107), animal stature(106) and glucose homeostasis (108).
Growth hormone is secreted by the pituitary into the circulation and promotes
IGF-1 expression in peripheral tissues, mainly in liver to promote cell growth
(109).
It is interesting that I found reduced cellular IGF1R and increased IGF-1in
circulation. This data indicated that reduced receptor level rendered the tissues
insensitive to the IGF-1 ligand. To maintain homeostasis, the tissues may
express more ligand to keep the balance. This is typically true in growth retarded
patients resistant toIGF-1 (110-113). This phenomenon is similar to type II
diabetes in which the tissues are resistant to insulin. Pancreas β-cells had to
express more insulin to keep normal glucose level after feeding. This will result
in high blood glucose level along with high insulin. When the IGF-1 level was
higher in 14-3-3ζ knockout mouse blood, a feedback signaling would make the
pituitary express less growth hormone. This may explain the phenomenon such
as delayed puberty onset and reduced blood glucose level I observed in the
animal.
Insulin, compared to IGF-1, is more efficient to promote glucose uptake but
tightly regulated by blood glucose level, whereas IGF-1 regulates glucose
homeostasis in a more consistent manner. IGF1R deletion also rendered the bislet cells secret lower insulin (114, 115). As to that the 14-3-3ζ knockout mice
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also displayed better glucose tolerance, it would be interesting to further
measure the insulin level and β-cell function in the knockout mouse and study
the differential role of insulin and IGF-1 in regulating glucose homeostasis.
GH/IGF-1 axis is also involved in puberty onset and mammary gland
development. I also observed that the mammary gland development is slightly
delayed in the 14-3-3ζ knockout mice matching the delayed puberty phenotype.
Meanwhile, the IGF1R also plays important role in breast cancer formation and
therapy resistance (116, 117). It is expected that IGF1R plays important role not
only in the delayed puberty, mammary gland development and aberrant glucose
homeostasis, but tumorigenesis and progression inhibition. Further study of how
14-3-3ζ regulates IGF1R may provide insight of breast cancer formation
progression and resistance to therapeutic regimens.
Recent studies suggest that metabolism plays important role in cancer
(118-120). Our data strongly suggested that 14-3-3ζ plays important role in
regulating metabolism likely through HIF1-α and IGF1R. Both of these genes
regulate cancer progression (121, 122). More interestingly both the genes
regulate angiogenesis (123-126). Many studies have suggested the important
role of 14-3-3ζ in cancer. 14-3-3ζ can be a new bridge linking cancer and
metabolism and provide new insight in cancer therapy.
I found that miR-126 was downregulated in 14-3-3ζ knockout embryos
lungs and tumors. It is also reported that miR-126 was reduced in type II
diabetes patients’ sera (79). Its role in diabetes is not clear yet. The 14-383

3ζ knockout mice may be resistant to insulin as indicated by better glucose
tolerance. It will be interesting to further investigate whether miR-126 is playing
some role mediating the energy deregulation caused by loss of 14-3-3ζ. Ptpn9
which is a target of miR-126 is a phosphotase of EGFR and ErbB2 (127, 128). It
has been reported to be involved in diabetes and cancer (129, 130). Currently I
am studying its role in both cancer and glucose homeostasis.
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3.5 Other phenotypes in 14-3-3ζ
ζ knockout mouse
The 14-3-3ζ knockout mice have other phenotypes to be further
characterized. For example, the 14-3-3ζ knockout mouse did not spread out the
rear limbs like the wild type mouse when lifted up via the tail, which suggested
neuronal degeneration phenotype (Figure 28). As 14-3-3ζ has been reported to
be involved in many human diseases as described in the introduction part of the
thesis, it would be interesting to further study the function of 14-3-3ζ in those
specific tissues.
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Figure 28. 14-3-3ζ knockout mice display phenotype indicative of neuronal
degenernation. The wild type mouse (left panel) spread the rear limbs outward
when lifted up. The knockout mouse (right panel) clasped.
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Chapter 4 Summary and Future Direction
In my thesis work, I generated a 14-3-3ζ hypomorphic mutant mouse
strain. This animal model displayed multiple phenotypes under different genetic
background such as neonatal lethality, delayed puberty, tumorigenesis inhibition
and aberrant glucose homeostasis. I studied the function of 14-3-3ζ using this
model and gained initial insight about the 14-3-3ζ role and the molecular
mechanisms mediating these in vivo.
I found different phenotypes in different genetic background. Loss of 14-3-3ζ
resulted in neonatal lethality in C57Bl/6 genetic background due to respiratory
failure. Loss of 14-3-3ζ inhibited tumorigenesis and progression in CD-1 and
FVB/N genetic background. 14-3-3ζ mice are smaller and have delayed puberty
onset in CD-1 strain. More phenotypes are to be characterized to study 14-3-3z
in vivo function.
Using this model, we can better understand the role of 14-3-3ζ in human
diseases like cancer. In the future, we may develop new target therapy related to
14-3-3ζ to treat and benefit patients in clinic.
This strain is a whole body knockout mouse model. Now we know tissue
microenvironment is critical for cellular function. A mouse model in which we can
conditionally or induciblely manipulate the 14-3-3ζ could help us better
understand the role of 14-3-3ζ in vivo. I designed a tetracycline inducible 14-33ζ transgenic mouse strategy and this transgenic mouse strain has been
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available in the lab now. We can generate more in depth insight of 14-3-3ζ
function using this model in the near future.
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